Acute Porphyria Drug Database

J07AH08 - Meningococcus A,C,Y,W-135, Tetravalent Purified Polysaccharides Antigen Conjugated
Propably not porphyrinogenic
PNP

Important Information
In general, vaccines are regarded safe since such substance is not suspected to give an up-regulation of the heme biosynthesis as a direct effect. However, some vaccines can lead to a reaction with high fever persisting over days as a side effect. It is possible that this side effect can trigger an acute porphyric attack in the same way as infections are known to. Vigilance is therefore motivated when administrating a vaccine known to cause reactions with fever.
Side effects
Fever is reported as a very common side effect the meningococcus A, C, Y, W-135 vaccine. A common adverse reaction of the vaccine that can be confused with an acute porphyric attack is nausea. This side effect may potentially be porphyrinogenic if leading to a decrease in carbohydrate intake.
Rationale
The active substances in the meningococcus A,C,Y,W-135 vaccine are conjugates of protein and oligosaccharides and with regards to its pharmacokinetics it has no conceivable porphyrinogenic effects.
Chemical description
The tetravalent meningococcus A, C, W, Y-135 conjugate vaccine consists of oligosaccharides derived from capsular polysaccharides of Neisseria meningitidis serogroups A, C, W and Y, each conjugated to a Corynebacterium diphtheriae-mutant carrier protein (EMA).
Therapeutic characteristics
The Meningococcus A,C,Y,W-135 vaccine is indicated for active immunization of children (from 2 years of age), adolescents and adults at risk of exposure to Neisseria meningitidis groups A, C, W135 and Y, to prevent invasive disease. It is administered by a single intramuscular injection.
Metabolism and pharmacokinetics
The meningococcus vaccine is not metabolized by the cytochrome P450 system.

References

  1. Government bodies
  2. European Public Assessment Report, Menveo (Scientific discussion).European Medicines Agency (EMA). Accessible from: ema.europa.eu #3198
  3. Norwegian Institute of Public Health. Vaksinasjonsveilederen. www.fhi.no (updated 13.10.2015) #1860
  4. Summary of Product Characteristics
  5. The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Menveo. #3199

Similar drugs
Explore alternative drugs in similar therapeutic classes J07A / J07AH or go back.

 
© NAPOS 2024
An unhandled error has occurred. Reload 🗙